Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antioxidant infusion may shield the heart from reperfusion injury

NCT ID NCT07776288

Disease control Sponsor: University of Chile Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combined antioxidant therapy—ascorbate, N-acetylcysteine, and deferoxamine—can reduce heart muscle damage when given before and during angioplasty for a first anterior ST-elevation heart attack. Adults eligible for primary PCI will be randomly assigned to receive the antioxidant infusion or a placebo, alongside standard care. The main goal is to see if the therapy lowers infarct size, measured by cardiac MRI a few days later, and improves heart function and blood markers of injury. Participants will be followed for 30 days to assess safety and short-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combined antioxidant therapy consisting of ascorbate (vitamin C), N-acetylcysteine, and deferoxamine, given as an infusion before and during primary PCI.
What this could lead to
If it works, this could lead to a simple, add-on treatment that limits permanent heart muscle damage after a heart attack, potentially improving recovery and reducing future heart failure risk.
What could go wrong
This is a small, early-phase trial, so results may not hold up in larger studies. The therapy could also cause side effects or fail to show a meaningful benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * First anterior ST-segment elevation myocardial infarction (STEMI) * Symptom onset within 6 hours before presentation * Eligible for primary percutaneous coronary intervention (PCI) * Provision of informed consent by the participant or a legally authorized representative, according to local ethics requirements Exclusion Criteria: * Prior myocardial infarction * Cardiogenic shock, defined as Society for Cardiovascular Angiography and Interventions (SCAI) shock class D or E. * Prior thrombolytic therapy for the index event. * Chronic kidney disease, defined as serum creatinine greater than 1.5 mg/dL or dialysis. * Liver cirrhosis * Advanced heart failure, defined as New York Heart Association (NYHA) class III or IV * Glucose-6-phosphate dehydrogenase (G6PD) deficiency * Nephrolithiasis * Life expectancy less than 6 months * Implanted cardiac device, including pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization device * Prior coronary artery bypass graft (CABG) surgery * Pregnancy * Claustrophobia * Other contraindications to cardiac magnetic resonance imaging (CMR), according to local protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction ischemia reperfusion injury myocardial infarction Myocardial Reperfusion Injury ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI) Reperfusion injuries, myocardial ST elevation (stemi) myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital San Juan de Dios

    Santiago, Santiago Metropolitan, 8170000, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.